Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Invested Capital (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Invested Capital for 6 consecutive years, with $123.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 48.91% to $123.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $123.1 million, a 48.91% decrease, with the full-year FY2025 number at $123.1 million, down 48.91% from a year prior.
  • Invested Capital was $123.1 million for Q4 2025 at TScan Therapeutics, down from $144.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $265.6 million in Q2 2024 to a low of -$60.0 million in Q2 2021.
  • A 5-year average of $141.5 million and a median of $150.0 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 599.57% in 2021, then crashed 48.91% in 2025.
  • TScan Therapeutics' Invested Capital stood at $160.8 million in 2021, then crashed by 38.15% to $99.4 million in 2022, then surged by 55.09% to $154.2 million in 2023, then soared by 56.26% to $241.0 million in 2024, then tumbled by 48.91% to $123.1 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Invested Capital are $123.1 million (Q4 2025), $144.0 million (Q3 2025), and $176.7 million (Q2 2025).